When Jessica Yingst's team at Penn State College of Medicine enrolled 104 people in a groundbreaking study, they set out to answer a question that has quietly shaped public health policy for years: can nicotine e-cigarettes actually help people escape cigarette smoking while reducing their exposure to deadly toxicants?
The answer, published in JAMA Network Open, is yes—and the effect is striking. Daily smokers who switched completely to a pod-based salt-nicotine e-cigarette were three times more likely to quit smoking within six weeks compared to those using an identical device containing no nicotine. The finding matters because cigarette smoking remains the leading preventable cause of death in the United States, even as smoking rates have fallen to an all-time low of about 10% in 2024.
What makes this research distinct is its precision. Researchers randomly assigned 52 participants to use a 5% nicotine e-cigarette and 52 to use a placebo device—an identical device delivering zero nicotine. Neither the researchers nor participants knew which group they belonged to. For six weeks, smokers were instructed to switch completely from cigarettes to their assigned device, with researchers measuring biomarkers of toxicant exposure at baseline, three weeks, and six weeks.
The key marker they tracked was NNAL, a compound that signals exposure to a potent lung carcinogen found only in tobacco leaf. This biomarker serves as a window into actual smoking exposure rather than reliance on self-reporting. The results revealed that participants using nicotine e-cigarettes had meaningfully lower levels of several tobacco-related toxicants in their bodies—evidence that the switch genuinely reduced harmful chemical exposure.
"For people who smoke and haven't been able to quit using approved medications, this research suggests that switching to a nicotine e-cigarette is associated with real reductions in harmful toxicant exposures and does support smoking cessation," said Yingst, associate professor of public health sciences and lead author on the study. The statement carries weight because it comes from a field that has long sought what public health experts call "off-ramps"—pathways that move people away from traditional combustible cigarettes toward less harmful products.
This distinction matters scientifically. Nicotine itself, while addictive, isn't the primary driver of smoking-related cancers and heart disease. Rather, burning tobacco produces byproducts—thousands of compounds created during combustion—that cause the majority of smoking-related harm. By switching to a device that delivers nicotine without burning tobacco, users can satisfy nicotine dependence while avoiding most of the toxicants that make cigarettes so deadly.
The research represents the first randomized placebo-controlled trial conducted in the United States to measure the effects of switching completely from cigarettes to pod-based salt-nicotine e-cigarettes—devices that use a nicotine salt formulation to deliver nicotine more smoothly and efficiently than older e-cigarette designs. That this trial needed to be conducted at all speaks to how quickly the e-cigarette landscape has transformed and how important it is to generate current evidence as products evolve.
For the millions of Americans who have tried and failed to quit using approved medications, this research opens a conversation about harm reduction as part of the toolkit for escaping smoking.